4.4 Article

Torin2 Suppresses Ionizing Radiation-Induced DNA Damage Repair

Journal

RADIATION RESEARCH
Volume 185, Issue 5, Pages 527-538

Publisher

RADIATION RESEARCH SOC
DOI: 10.1667/RR14373.1

Keywords

-

Funding

  1. CPRIT Grant [R1207]
  2. NIH [CA129537, GM109768]
  3. Lung Cancer SPORE [P50CA70907]

Ask authors/readers for more resources

Several classes of inhibitors of the mammalian target of rapamycin (mTOR) have been developed based on its central role in sensing growth factor and nutrient levels to regulate cellular metabolism. However, its ATP-binding site closely resembles other phosphatidylinositol 3-kinase-related kinase (PIKK) family members, resulting in reactivity with these targets that may also be therapeutically useful. The ATP-competitive mTOR inhibitor, Torin2, shows biochemical activity against the DNA repair-associated proteins ATM, ATR and DNA-PK, which raises the possibility that Torin2 and related compounds might radiosensitize cancerous tumors. In this study Torin2 was also found to enhance ionizing radiation-induced cell killing in conditions where ATM was dispensable, confirming the requirement for multiple PIKK targets. Moreover, Torin2 did not influence the initial appearance of gamma-H2AX foci after irradiation but significantly delayed the disappearance of radiation-induced gamma-H2AX foci, indicating a DNA repair defect. Torin2 increased the number of radiation-induced S-phase specific chromosome aberrations and reduced the frequency of radiation-induced CtIP and Rad51 foci formation, suggesting that Torin2 works by blocking homologous recombination (HR)-mediated DNA repair resulting in an S-phase specific DNA repair defect. Accordingly, Torin2 reduced HR-mediated repair of I-Sce1-induced DNA damage and contributed to replication fork stalling. We conclude that radiosensitization of tumor cells by Torin2 is associated with disrupting ATR- and ATM-dependent DNA damage responses. Our findings support the concept of developing combination cancer therapies that incorporate ionizing radiation therapy and Torin2 or compounds with similar properties. (C) 2016 by Radiation Research Society

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Biotechnology & Applied Microbiology

PD-L1P146R is prognostic and a negative predictor of response to immunotherapy in gastric cancer

Qing Li, Zhi-Wei Zhou, Jia Lu, Hao Luo, Shu-Nan Wang, Yu Peng, Meng-Sheng Deng, Guan-Bin Song, Jian-Min Wang, Xi Wei, Dong Wang, Kenneth D. Westover, Cheng-Xiong Xu

Summary: This study found that the rs17718883 polymorphism in the PD-L1 gene affects the PD-1/PD-L1 interaction, leading to ineffectiveness of PD-1/PD-L1 blockade therapy in certain gastric cancer patients. The study suggests that rs17718883 could be used as a screening biomarker to exclude patients who are not suitable for PD-1/PD-L1 blockade therapy.

MOLECULAR THERAPY (2022)

Editorial Material Biochemistry & Molecular Biology

The to and fro of Rho

Kenneth D. Westover

Summary: The functions of Ras members are largely determined by the structural dynamics of the nucleotide-binding switch regions. In this study, Lin et al. focus on the dynamic equilibrium of RhoA to gain insights into the working mechanism of the Ras GTPase family.

STRUCTURE (2021)

Article Biochemistry & Molecular Biology

The nonreceptor tyrosine kinase SRMS inhibits autophagy and promotes tumor growth by phosphorylating the scaffolding protein FKBP51

Jung Mi Park, Seung Wook Yang, Wei Zhuang, Asim K. Bera, Yan Liu, Deepak Gurbani, Sergei J. von Hoyningen-Huene, Sadie Miki Sakurada, Haiyun Gan, Shondra M. Pruett-Miller, Kenneth D. Westover, Malia B. Potts

Summary: Nutrient-responsive protein kinase SRMS inhibits autophagy and promotes growth in vertebrates, and is amplified in human cancers. Inhibition of SRMS kinase activates autophagy, inhibits cancer growth, and can be achieved using the FDA-approved tyrosine kinase inhibitor ibrutinib.

PLOS BIOLOGY (2021)

Article Chemistry, Organic

Acid-Catalyzed Synthesis of Isatoic Anhydride-8-Secondary Amides Enables IASA Transformations for Medicinal Chemistry

Sudershan R. Gondi, Althaf Shaik, Kenneth D. Westover

Summary: A new method for synthesizing substituted quinazolin-dione-N-3-alkyl derivatives from isatin was reported, which is low-cost and scalable, suitable for the synthesis of various derivatives with medicinal uses.

JOURNAL OF ORGANIC CHEMISTRY (2022)

Review Biochemistry & Molecular Biology

Therapeutic Targeting the Allosteric Cysteinome of RAS and Kinase Families

Lianbo Li, Cynthia Meyer, Zhi-Wei Zhou, Ammar Elmezayen, Kenneth Westover

Summary: Allosteric mechanisms are common in nature but rare in human-designed perturbagens. The development of KRAS(G12C) inhibitors suggests that covalent chemistry could expand the use of allosteric inhibitors. This study explores the feasibility of extending this approach to other proteins in the RAS and kinase family, which play important roles in cellular processes, especially in cancer therapy.

JOURNAL OF MOLECULAR BIOLOGY (2022)

Article Multidisciplinary Sciences

ADAP1 promotes latent HIV-1 reactivation by selectively tuning KRAS-ERK-AP-1 T cell signaling-transcriptional axis

Nora-Guadalupe P. Ramirez, Jeon Lee, Yue Zheng, Lianbo Li, Bryce Dennis, Didi Chen, Ashwini Challa, Vicente Planelles, Kenneth D. Westover, Neal M. Alto, Ivan D'Orso

Summary: This study revealed an undescribed modulator, ADAP1, that influences the fate of HIV-1 provirus. The experimental results showed that ADAP1 can enhance T cell signaling and facilitate the escape of latent HIV-1 by activating the ERK-AP-1 axis.

NATURE COMMUNICATIONS (2022)

Article Oncology

T Stage and Pretreatment Standardized Uptake Values Predict Tumor Recurrence With 5-Fraction SABR in Early-Stage Non-Small Cell Lung Cancer

Eric J. Hsu, Jameson T. Mendel, Kristin A. Ward, Mariam El-Ashmawy, Minjae Lee, Hak Choy, Kenneth D. Westover, Dat T. Vo, Robert D. Timmerman, David J. Sher, Puneeth Iyengar

Summary: This study analyzed the treatment outcomes of 90 patients with T1-2 non-small cell lung cancer who received five-fraction stereotactic ablative radiotherapy (SABR). The results identified the clinical parameters predictive of treatment failures with these regimens, providing guidance for treatment selection.

ADVANCES IN RADIATION ONCOLOGY (2022)

Article Chemistry, Medicinal

Synthesis and Structure-Activity relationships of cyclin-dependent kinase 11 inhibitors based on a diaminothiazole scaffold

Zhengnian Li, Ryosuke Ishida, Yan Liu, Jinhua Wang, Yina Li, Yang Gao, Jie Jiang, Jianwei Che, Jason M. Sheltzer, Matthew B. Robers, Tinghu Zhang, Kenneth D. Westover, Behnam Nabet, Nathanael S. Gray

Summary: This study describes a medicinal chemistry campaign to identify a CDK11 inhibitor. Through structure-guided medicinal chemistry modifications, a CDK11 probe ZNL-05-044 with improved selectivity was identified, which can arrest cell cycle and impact CDK11-dependent gene splicing in cells.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2022)

Article Biochemistry & Molecular Biology

Thermal Shift Assay for Small GTPase Stability Screening: Evaluation and Suitability

Kari Kopra, Salla Valtonen, Randa Mahran, Jonas N. Kapp, Nazia Hassan, William Gillette, Bryce Dennis, Lianbo Li, Kenneth D. Westover, Andreas Plueckthun, Harri Harma

Summary: Thermal unfolding methods are commonly used to predict protein's thermal stability and to screen potential drugs. Differential scanning calorimetry is considered the gold standard, but other methods like differential scanning fluorimetry are also used. These methods have relatively low sensitivity. By comparing three thermal stability probes, researchers found that the Protein-Probe is more sensitive and can work at lower concentrations.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Article Chemistry, Medicinal

Development of a Covalent Inhibitor of c-Jun N-Terminal Protein Kinase (JNK) 2/3 with Selectivity over JNK1

Wenchao Lu, Yao Liu, Yang Gao, Qixiang Geng, Deepak Gurbani, Lianbo Li, Scott B. Ficarro, Cynthia J. Meyer, Dhiraj Sinha, Inchul You, Jason Tse, Zhixiang He, Wenzhi Ji, Jianwei Che, Audrey Y. Kim, Tengteng Yu, Kenneth Wen, Kenneth C. Anderson, Jarrod A. Marto, Kenneth D. Westover, Tinghu Zhang, Nathanael S. Gray

Summary: In this study, the researchers discovered a specific inhibitor, YL5084, which demonstrates selectivity for JNK2 over JNK1. YL5084 forms a covalent bond with Cys116 of JNK2 and exhibits higher K-inact/K-I than JNK1. However, YL5084 also shows JNK2-independent antiproliferative effects in multiple myeloma cells, suggesting the presence of additional targets in this context. Although not fully optimized, YL5084 represents a useful chemical starting point for developing JNK2-selective chemical probes in the future.

JOURNAL OF MEDICINAL CHEMISTRY (2023)

Article Chemistry, Multidisciplinary

LIMS-Kinase provides sensitive and generalizable label-free in vitro measurement of kinase activity using mass spectrometry

Cynthia Meyer, Melissa McCoy, Lianbo Li, Bruce Posner, Kenneth D. Westover

Summary: Measurements of kinase activity are crucial for drug development and understanding drug resistance mechanisms. A label-free, high-throughput mass spectrometry-based assay is described for studying individual kinase enzymology and drug discovery. This approach is adaptable to various kinase substrates and offers increased sensitivity. It has the potential for research on understudied kinases and kinase drug discovery.

CELL REPORTS PHYSICAL SCIENCE (2023)

Meeting Abstract Radiology, Nuclear Medicine & Medical Imaging

Development and Validation of Strong Tesla Electron Return Effect Reduction (STEER) Planning Technique for Centrally Located Lung Radiotherapy with MR-Linac System

J. Visak, B. Cai, M. Lin, A. Pompos, A. Godley, P. Iyengar, C. Park, K. Westover

MEDICAL PHYSICS (2022)

Meeting Abstract Radiology, Nuclear Medicine & Medical Imaging

An Automated Solution to Presenting Dose Distributions of Radiotherapy in a Hospital Information System

J. Wu, J. Lin, A. Pompos, D. Sher, K. Westover, R. Timmerman, S. Jiang, Y. Yan

MEDICAL PHYSICS (2022)

Meeting Abstract Radiology, Nuclear Medicine & Medical Imaging

Benchmark CBCT-Based Adaptive Online Radiotherapy for SAbR of Thoracic Malignancies

Y. Gonzalez, B. Meng, D. Parsons, B. Hrycushko, T. Zhuang, B. Cai, Y. Zhang, K. Westover, P. Iyengar, A. Godley, S. Jiang, M. Lin

MEDICAL PHYSICS (2022)

Article Oncology

ULK1 inhibition overcomes compromised antigen presentation and restores antitumor immunity in LKB1-mutant lung cancer

Jiehui Deng, Aatish Thennavan, Igor Dolgalev, Ting Chen, Jie Li, Antonio Marzio, John T. Poirier, David H. Peng, Mirna Bulatovic, Subhadip Mukhopadhyay, Heather Silver, Eleni Papadopoulos, Val Pyon, Cassandra Thakurdin, Han Han, Fei Li, Shuai Li, Hailin Ding, Hai Hu, Yuanwang Pan, Vajira Weerasekara, Baishan Jiang, Eric S. Wang, Ian Ahearn, Mark Philips, Thales Papagiannakopoulos, Aristotelis Tsirigos, Eli Rothenberg, Justin Gainor, Gordon J. Freeman, Charles M. Rudin, Nathanael S. Gray, Peter S. Hammerman, Michele Pagano, John V. Heymach, Charles M. Perou, Nabeel Bardeesy, Kwok-Kin Wong

Summary: The study found that LKB1-deficient lung tumors are sensitive to autophagy inhibition, which can restore impaired antigen presentation and antitumor immune responses, enhancing the effectiveness of PD-1 immunotherapy. Additionally, LKB1 deficiency inhibits antigen processing and presentation, but this can be reversed by targeting the autophagy pathway to restore immunoproteasome activity and antigen presentation.

NATURE CANCER (2021)

No Data Available